Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 2.67 percent decrease over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $20.874 million which missed the analyst consensus estimate of $21.420 million by 2.55 percent. This is a 36.54 percent increase over sales of $15.288 million the same period last year.